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Abstract The ability to deliver drug molecules effec-
tively across the blood–brain barrier into the brain is
important in the development of central nervous system
(CNS) therapies. Cerebral microdialysis is the only existing
technique for sampling molecules from the brain extra-
cellular fluid (ECF; also termed interstitial fluid), the
compartment to which the astrocytes and neurones are
directly exposed. Plasma levels of drugs are often poor
predictors of CNS activity. While cerebrospinal fluid (CSF)
levels of drugs are often used as evidence of delivery of
drug to brain, the CSF is a different compartment to the
ECF. The continuous nature of microdialysis sampling of
the ECF is ideal for pharmacokinetic (PK) studies, and can
give valuable PK information of variations with time in
drug concentrations of brain ECF versus plasma. The
microdialysis technique needs careful calibration for rela-
tive recovery (extraction efficiency) of the drug if absolute
quantification is required. Besides the drug, other mole-
cules can be analysed in the microdialysates for informa-
tion on downstream targets and/or energy metabolism in
the brain. Cerebral microdialysis is an invasive technique,
so is only useable in patients requiring neurocritical care,
neurosurgery or brain biopsy. Application of results to
wider patient populations, and to those with different
pathologies or degrees of pathology, obviously demands
caution. Nevertheless, microdialysis data can provide
valuable guidelines for designing CNS therapies, and
play an important role in small phase II clinical trials. In
this review, we focus on the role of cerebral microdi-
alysis in recent clinical studies of antimicrobial agents,
drugs for tumour therapy, neuroprotective agents and
anticonvulsants.
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Introduction
Our knowledge and understanding of the central nervous
system (CNS) disorders has increased greatly in the last
two decades, along with rapidly advancing technology.
However, these advances have not been matched by an
increase in the number of new pharmacological agents to
treat and prevent neurological and neuropsychiatric disor-
ders. The development of new CNS drugs is fraught with
difficulty. A recent survey reports that as little as 8 % of
CNS drug candidates ever become available for clinical
use, compared with 15 % of other drugs [1]. The report
also suggests that trial failures tend to occur later in the
clinical development process, when costs are highest.
Reasons for failures include inadequate clinical efficacy,
inadequate clinical safety (e.g. harmful side effects), and
lack of detailed and accurate information about how the
drug enters and functions in the brain. In order to translate
our knowledge and understanding into clinical applications
and novel therapies, more detailed early clinical studies
need to be carried out to select drug candidates that are
likely to be successful in clinical trials. Especially
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important are pharmacokinetic studies that help us to gain a
better understanding of drug bioavailability in, and elimi-
nation from, the human brain.
An earlier review by Helmy et al. [2] gives a thorough
account of the microdialysis method and highlights its
potential role in the development and clinical assessment of
drugs. Alavijeh and Palmer [3] have recently reviewed the
pharmacokinetic and pharmacodynamic properties of neu-
roactive compounds, concentrating on cerebral microdi-
alysis studies using animals. An older review by de la Pen˜a
et al. [4] gives an overview of the use of microdialysis in
peripheral tissues. In the present review, we focus on recent
drug studies using microdialysis to sample the extracellular
fluid of the human brain.
The compartments of the brain
Developing improved treatments for CNS disorders such as
epilepsy, traumatic brain injury (TBI), stroke, brain tumours,
Parkinson’s disease and Alzheimer’s disease requires more
accurate and detailed data about human neuro-pharmacoki-
netics and neurochemistry. Disorders of the brain involve
biochemical mediators, so the monitoring and manipulation
of brain chemistry is essential for developing and evaluating
new treatments. Neuroactive drugs are likely to interact with
endogenous pathways in the brain involving such species as
neurotransmitters, amino acids, reactive oxygen species,
membrane transporters and enzymes. An added complexity
of treating CNS disorders is the strict compartmentalisation
of the brain interstitium from the blood circulation by the
blood–brain barrier (BBB) (see section entitled ‘‘The blood-
brain barrier’’).
In order to interact with molecules or receptors inside
the brain, a drug must first enter the brain and be sustain-
able at a pharmacologically relevant concentration at the
target site. Small, lipophilic molecules can diffuse through
the BBB to get into the brain. Otherwise, a drug must either
be transported by a membrane transporter or gain access
through compromised BBB [5, 6]. Once inside the brain,
drug molecules can be unbound (free) in the extracellular
fluid (ECF), or taken up into cells or bound to membranes
or extracellular matrix. Drugs can also be transported back
out of the brain by an efflux transporter. The proportion of
free drug that remains in the ECF can gain access to glial
cells and neurons, or bind to membrane transporters, car-
rying out its pharmacological function at the target site
(Fig. 1) [7, 8]. Therefore, developing neuroactive drugs
requires an understanding of the pharmacokinetics of the
drug in the brain as well as in blood. Being able to measure
the amount of free drug in brain ECF is essential to assess
whether a putative neuroactive drug is likely to work.
The clearance of a drug from the brain is also complex.
The ECF drains (passively) into the cerebrospinal fluid
(CSF); there is no barrier to this transport [9]. Chemicals in
the ECF may find their way into the CSF by this route or
they may be actively transported back into the blood,
across the BBB. If the drug is actively transported out of
the ECF, it may be difficult to maintain a pharmacologi-
cally relevant concentration at the target site. For this
reason, information about how the drug is cleared from the
brain should also be evaluated in early clinical studies.
Cerebral microdialysis is the only technique that enables
us to directly sample molecules from the brain ECF. It is
therefore the gold standard technique for evaluating CNS
drug pharmacokinetics in vivo during early drug develop-
ment [10].
Cerebral microdialysis
Microdialysis enables the chemistry of ECF in body tissues
to be monitored. The technique has been used in patients
with severe brain conditions such as TBI, subarachnoid
haemorrhage, brain tumours and epilepsy. A microdialysis
catheter tip is implanted into the cerebral parenchyma
(brain tissue). The catheter tip consists of two concentric
tubes where the outer wall is a semi-permeable microdi-
alysis membrane. Perfusion fluid (a solution of 147 mM
Fig. 1 Extracellular fluid is the key compartment for the action of a
neuroactive compound. The diagram is adapted from Alavijeh et al.
[7] and Shen et al. [8]. BBB is Blood–brain barrier. BCSFB is blood–
cerebrospinal fluid barrier. BCSFB influx and efflux is via the choroid
plexus, which is also the major source of CSF. A Bulk flow of ECF to
CSF with no barrier. B CSF fluid (and solutes) are absorbed into
venous blood via the arachnoid villi. C Uptake of drug into cells is
either passive or transporter driven, similarly for efflux from cells.
Biological effect is usually due to interaction of drug with a
membrane receptor or an intracellular target
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NaCl, 2.7 mM KCl, 1.2 mM CaCl2, 0.85 mM MgCl2 in
water) is pumped through the space between the dialysis
membrane and the inner tube at a low flow rate, typically
0.3 ll/min. The microdialysis membrane allows molecules
to diffuse in both directions between the brain ECF and the
perfusion fluid in the catheter. The end of the catheter is
closed so that the perfusion fluid returns back up the central
tube of the catheter to be collected in a vial (Fig. 2). The
catheter enables sampling of the molecules from the ECF
of the tissue into which it has been implanted.
Substances of interest in brain ECF include markers of
brain metabolism (e.g. glucose, lactate, pyruvate), neuro-
transmitters (e.g. glutamic acid, aspartic acid, GABA),
markers of membrane damage (e.g. glycerol) and inflam-
mation (e.g. cytokines), as well as drugs.
There are many examples where microdialysis has been
used in animal studies to help elucidate the neuro-phar-
macokinetics of certain drugs [3]. Excellent data can be
gathered from regular blood sampling and cerebral
microdialysis, and conclusions drawn about the interplay
between blood and brain. These studies are used to predict
therapeutic doses and dosing intervals for human clinical
trials. However, there may be significant differences
between how the drug behaves in an animal model and in
humans. For example, there may be different substrate-
specific transporters operating at the BBB (see section
entitled ‘‘Genetic polymorphism and BBB transporters in
patients’’). The most relevant pharmacokinetic data come
from human studies. However, cerebral microdialysis is an
invasive technique that cannot be applied to healthy human
volunteers. Cerebral microdialysis studies have been car-
ried out on patients undergoing biopsy or tumour resection,
surgery for severe epilepsy, or undergoing neurocritical
care after severe brain injury (e.g. head injury and certain
types of stroke) where microdialysis is part of
multimodality monitoring. Microdialysis catheters are
inserted into the brain either via a craniotomy or via a burr-
hole. A triple-lumen cranial access device (Technicam,
Newton Abbot, UK) can be used to insert the microdialysis
catheter alongside probes for measuring intracranial pres-
sure and brain tissue oxygen, all through the same burr
hole, for multimodality monitoring (Fig. 3) [11]. Some-
times two microdialysis catheters—for example, one in
abnormal brain (usually via a craniotomy) in the vicinity of
a focal lesion, and one in brain distant from a focal lesion
(usually via a cranial access device through a burr hole)—
are deployed within the same patient.
The blood–brain barrier
The BBB is a specialised neurovascular unit formed by
neurons, astrocytes, pericytes, basal lamina, and endothelial
cells. In contrast to the relatively permeable fenestrated
endothelium of the peripheral vasculature, the endothelial
cells of brain microvessels are linked by apical tight junc-
tions and form a continuous barrier that prohibits paracel-
lular diffusion of all but small (\400 Da) lipophilic
molecules. Exchange of molecules between blood and brain
interstitum is thus highly restricted and regulated by multiple
families of solute transporters for small molecules (e.g.
glucose and amino acids) and endo- and trans-cytosis sys-
tems for larger proteins [12, 13]. Furthermore, the BBB
possesses highly effective efflux transporters to remove
toxins and drugs from the CNS (Schwab et al. [12]). In
combination, these mechanisms present significant chal-
lenges to developing therapeutic agents that efficiently
penetrate and are sustained in the brain at pharmacologically
relevant concentrations. Accordingly, drugs with CNS
actions are generally highly lipophilic (e.g. anaesthetic
agents), are mimetics of natural substrates to BBB
Fig. 2 Schematic of the
microdialysis catheter tip.
Substances in the extracellular
fluid outside the catheter tip are
able to diffuse across the
microdialysis membrane to be
collected for analysis
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transporters, or are dependent on BBB disruption to enter the
CNS. Fortuitously from this perspective, increased BBB
permeability is a common feature of many CNS pathologies
(e.g. meningitis, primary and secondary tumours, intracere-
bral haemorrhage, and traumatic injury). If the BBB is not
significantly affected by a disease process, therapeutic
strategies have been developed to temporarily open the BBB
by intravenous infusion of hypertonic agents (e.g. mannitol)
prior to drug delivery [13] or to co-administer agents that
block efflux transporters [14].
Cerebral microdialysis in clinical studies of drugs
Microdialysis enables measurement of drug concentration
in brain ECF, on a continuous basis. Microdialysis can thus
demonstrate whether a drug in question, at an appropriate
dosage, can cross the BBB at sufficient concentration.
Resources can then be channelled to drug candidates that
have the best chance of showing efficacy in larger-scale
clinical trials.
Data from a small clinical study involving only a few
patients in a neurocritical care unit may be sufficient to
show whether a particular drug candidate might be worth
pursuing or not. A microdialysis study by Hutchinson et al.
[15] investigated the effect of the potentially neuropro-
tective drug chlormethiazole on neurochemistry in five TBI
patients. This drug proved to be undetectable in brain mi-
crodialysates, suggesting an adequate concentration of the
drug did not reach the target site to exert its mechanism of
action. Interestingly, in a phase III clinical trial chlorme-
thiazole did not improve the outcome in patients with
major ischemic stroke [16]. This expensive, time-con-
suming and unsuccessful phase III trial could potentially
have been avoided by first carrying out an in vivo micro-
dialysis study [10].
Cerebral microdialysis is not only useful for assessing
drug penetration into the brain, but is also used to monitor
the effect of neuroactive drugs on brain chemistry. Moni-
toring endogenous compounds such as neurotransmitters
and metabolic markers can provide evidence of whether a
drug is affecting its target in the desired manner. It can also
be used to help assess the clinical safety of the drug, e.g.
whether there are any adverse changes in microdialysate
levels of glucose, lactate, pyruvate, glutamate and glycerol.
The following section highlights a number of studies
where cerebral microdialysis has been used to extract
pharmacokinetic parameters from small clinical studies.
The examples are arranged by therapeutic area: antibacte-
rial agents, tumour therapy, neuroprotective agents and
anticonvulsant drugs.
Antibacterial agents
CNS infections such as bacterial meningitis are routinely
treated with b-lactam antibiotics, such as the carbapenems.
Antibiotics for treating CNS infections must be able to
maintain a minimum inhibitory concentration (MIC) in the
brain. The MIC of a drug is the concentration required to
kill a particular strain of bacteria and is measured in vitro.
These antibiotics, like any neuroactive drug, must not have
a neurotoxic effect at therapeutic concentrations. Some of
the carbapenem antibiotics, such as imipenem, can cause
an increase in the frequency of seizures if over-dosed [17].
Others, such as meropenem, are less neurotoxic and
therefore safe to use for the treatment of bacterial menin-
gitis. In the following two examples, cerebral microdialysis
has been used to evaluate the actual concentration of drug
in the brain.
In a study by Dahyot-Fizelier et al. [18] an intravenous
infusion containing meropenem was given to two patients
being treated for acute brain injury in the neurocritical care
unit (NCCU). Microdialysis sampling of brain ECF and
other routine monitoring used in the NCCU was carried
Fig. 3 A triple lumen cranial access device (CAD) is inserted into the
skull, to provide access into the brain for the microdialysis catheter
(MD) and for sensors measuring intracranial pressure (ICP) and brain
tissue oxygen concentration (O2). A pump (not shown) drives the
syringe that delivers perfusion fluid into the microdialysis catheter,
and the microdialysate emerges from the brain into a collection vial.
The vial is changed hourly by a nurse and analysed at the bedside on a
clinical microdialysis analyser (ISCUS or CMA600, for glucose,
lactate, pyruvate, glutamate and glycerol) and in the laboratory for
other analytes (e.g. drugs) as desired. Image copyright K.L.H.
Carpenter and reproduced here with her permission
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out, and blood samples were taken. In another study by
Poeppl et al. [19], an intravenous infusion containing the
new broad-spectrum antibiotic, doripenem, was given to
five neuro-intensive care patients, and they were similarly
monitored.
Dahyot-Fizelier et al. [18] found that the brain ECF
concentrations of meropenem were lower than the blood
serum concentrations. The ratio of drug in brain ECF to
drug in serum was calculated from the area under the
concentration–time curves (AUC) and found to be 0.73 and
0.14 for the two patients. The time course of meropenem
concentration in serum and brain ECF (Fig. 4) showed
delayed distribution in brain ECF from the blood. The
authors developed a pharmacokinetic model to fit their
experimental data, and thereby estimated various pharma-
cokinetic parameters for blood and brain. They concluded
that the brain ECF concentration was lower than the serum
concentration due to active efflux transport systems at the
BBB. It is interesting to compare the pharmacokinetic
results of this study with an older study by Nau et al. [20]
who measured the meropenem concentration in CSF and
serum from ten patients with an external ventricular drain.
These patients had occlusive hydrocephalus resulting from
cerebrovascular causes. Nau et al. [20] found a CSF-to-
serum ratio of 0.047 ± 0.022, about one-tenth of the ECF-
to-serum ratio found by Dahyot-Fizelier et al. [18] in the
microdialysis study. This might be due to a difference in
penetration of the two brain compartments (ECF and CSF),
and/or to differences in pathology of the patients being
studied.
The second microdialysis study example of an antibac-
terial agent was by Poeppl et al. [19], who found AUC
values for doripenem in brain ECF were much lower than
those for blood. The brain-to-serum AUC ratio for one of
the head-injured patients in this study was 0.17, which is
the same order of magnitude as for the meropenem
patients. However, the AUC ratio for the remaining four
patients was 0.01, indicating that very little drug appeared
to cross the BBB. The authors found that the concentration
of doripenem was so low that the drug would not reach the
required time above the MIC for many strains of bacteria.
The authors speculated that doripenem might not be a
substrate for a BBB influx transporter, or that inhibition of,
or genetic polymorphism in a particular transporter affects
the drug concentration in brain ECF. They also suggested
that the high AUC ratio seen in one patient could be due to
local impairment of BBB integrity in that individual.
These two studies highlight one of the complications of
carrying out pharmacokinetic studies of a drug on a small
number of head injury patients: the patients are a hetero-
geneous group of individuals. They will inevitably have
genetic differences and will have suffered varying degrees
of brain injury, leading to variable loss of BBB integrity.
An abnormal BBB is likely to be more permeable than
Fig. 4 Pharmacokinetics of
meropenem in serum and brain
ECF, from a study by Dahyot-
Fizelier et al. [18]. Individual
concentrations of meropenem in
serum (white circle), and in
brain extracellular fluid (ECF)
measured using microdialysis
(black circle), plotted versus
time in two critical-care patients
(acute brain injury) after a
30-min intravenous infusion of
1 g of meropenem administered
every 8 h during a multiple-
dosing regimen. The solid line
represents the predicted
concentrations in serum, and the
dashed line represents the
predicted concentrations in
brain. Copyright: American
Society for Microbiology
[Antimicrobial Agents and
Chemotherapy, 54: 3502–3504,
doi:10.1128/AAC.01725-09]
and reproduced with permission
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normal BBB and therefore facilitate drug entry into the
brain [21]. The drug may be a substrate for a number of
receptors or transporters, and interact with many molecular
species present in the brain. Aberrant states of brain
chemistry often prevail after TBI (and vary with time, as
well as within- and between-patient), evidenced by eleva-
tions in lactate, lactate/pyruvate ratio, glutamate and
glycerol [74, 75], suggesting hypoxia and/or mitochondrial
dysfunction, excitotoxicity and cell membrane breakdown,
all of which could potentially affect the pharmacokinetics
and pharmacodynamics of a drug in the brain. Also, we do
not know which factors affect drug influx and efflux for a
particular drug and patient. The patients may have
numerous clinical features that will influence drug distri-
bution in the blood and within brain (e.g. sites close to and
distant from focal lesions). The above considerations may
limit the potential to extrapolate pharmacokinetic findings
from critically injured patients to a different (non-TBI)
patient group.
Given the above limitations, the above two studies
(meropenem and doripenem) are good examples of using
cerebral microdialysis in human patients to extract basic
pharmacokinetic parameters such as AUC, maximum
concentration of drug (Cmax), time taken to reach Cmax,
elimination rate constants and half-life of drug in brain, in
parallel with blood pharmacokinetics. Pharmacokinetic
analysis is possible because of the quality and quantity of
data that can be accessed by microdialysis, which is a
continuous sampling technique. The CSF can be taken
from patients, though this fluid is less relevant for the
action of a neuroactive drug than the ECF. We postulate
that the brain extracellular space (which can be accessed by
microdialysis) is a more relevant compartment than CSF, in
the context of biological activity, since the ECF is directly
in contact with neurons and astrocytes, whereas CSF is not.
CSF samples can be taken from sedated patients on the
neuro-intensive care unit using an external ventricular
drain from a brain ventricle, or CSF can be taken by lumbar
puncture from the spinal subarachnoid space. In the latter
case, sampling would be much less frequent than micro-
dialysis sampling. Furthermore, Shore et al. [22] have
demonstrated that the volume and frequency of CSF sam-
pling has an effect on the measured concentration of sev-
eral cytokines in the CSF. This would suggest that CSF is
acting as a ‘sump’ or excretion mechanism from the brain
rather than accurately reflecting brain biology and
emphasises the point that the CSF and ECF compartments
are distinct entities [23].
As a comparison with the study by Poeppl et al., Mar-
gentis et al. [24] reported the CSF concentration of do-
ripenem in five neurosurgical patients during implantation
of an intrathecal baclofen infusion pump to treat spasticity.
The CSF samples were taken from the spinal subarachnoid
space at different times after intravenous infusion of
doripenem, given prophylactically prior to the operation.
None of the patients had active neurological diseases or
infections, and the authors regarded the BBB as intact.
They were unable to carry out pharmacokinetic calcula-
tions because only one sample was taken from each patient.
However, the study did suggest that doripenem penetrated
the intact BBB of these patients.
Other clinical studies of antibacterial agents by cere-
bral microdialysis include vancomycin in TBI patients
(Caricato et al. [25]), rifampicin in brain tumour patients
(Mindermann et al. [26]), and cefotaxime in a TBI patient
(Frasca et al. [27]). Microdialysis can thus provide
important evidence as to whether sufficient concentrations
can be attained in brain to kill bacteria, although with the
caveat that BBB permeability may vary considerably
between patients. In their recent review, Notkina et al. [28]
have remarked that treatment of cerebral infections is still a
challenge and that some of the dosages of antibacterial
drugs may be inadequate for more resistant bacteria despite
seemingly effective plasma concentrations. Cerebral
microdialysis studies with pharmacokinetic/pharmacody-
namic modelling allow prediction of effectiveness of
altered drug regimens and can thus form the basis of more
accurate dosage for patients with CNS infections [28].
The two microdialysis studies of the antimicrobial
agents meropenem and doripenem demonstrate another
important point: the different approaches to calibrating the
relative recovery (also termed extraction efficiency) of the
microdialysis catheters. Dahyot-Fizelier et al. [18] were
able to measure the recovery of meropenem in each patient
using the retrodialysis-by-drug method. This method
involves adding a known concentration of the drug to the
perfusion fluid being pumped into the catheter (see also
section entitled ‘‘In vivo recovery experiments’’ below).
After such time that a steady state is reached, the con-
centration of drug in the microdialysate is measured and
compared to the concentration of drug initially added to the
perfusion fluid. Dahyot-Fizelier et al. found relative
recoveries of 19 ± 7 and 29 ± 7 % for the two patients
and calculated brain concentrations of meropenem using
these correction factors. Poeppl et al. [19] did not carry out
in vivo recovery due to concerns about high concentrations
of doripenem in the brain provoking seizures. Instead, they
used a value of 38 % recovery that they determined pre-
viously, using the microdialysis catheters in soft tissue
experiments (unpublished results). The very low apparent
brain penetration of doripenem in four out of the five
patients in this study might be partly due to low recovery in
these particular catheters. However, the authors point out
that the flow rate (0.3 ll/min) should be low enough to
allow sufficient transfer across the microdialysis
membrane.
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While in vivo catheter calibration is preferable, it is not
always possible, e.g. if the drug is not available in a sterile
preparation or if it is otherwise unfeasible to perfuse the
drug directly into the brain. Although in vitro microdialysis
recovery experiments are only an approximation of how
the catheter performs in vivo, they are essential to our
understanding of molecular transfer across the microdi-
alysis catheter membrane. Generally, small water-soluble
molecules are recovered with high % recovery in labora-
tory testing, and the lower the flow rate, the higher the %
recovery [29–31]. Larger molecules, such as cytokines and
chemokines, tend to have lower relative recoveries,
depending on physicochemical factors including apparent
molecular weight (taking into account dimerization, tri-
merization, etc.) and isoelectric point (pI) [32].
Drugs for tumour therapy
Anticancer drugs for treating brain tumours must be able to
cross the BBB and accumulate in the tumour tissue at a
high enough concentration for a sufficient time to kill
tumour cells. Inadequate penetration of the BBB is a sig-
nificant hurdle for chemotherapy agents in the treatment of
cancerous brain tumours [33]. Factors hindering delivery of
drugs across the BBB include the multidrug resistance
proteins (MRPs) and ATP-dependent efflux pumps such as
P-glycoprotein (P-gp), which act as efflux transporters that
limit drug access to brain, and to brain tumours. Two recent
studies show how microdialysis can be used to assess
bioavailability in the development of new anticancer drugs.
Portnow et al. [34] placed microdialysis catheters into
residual tumour or peritumoral brain interstitium and
measured the concentration of the anti-cancer drug
temozolomide after a single oral dose. Temozolomide is a
pro-drug that metabolizes in the body to MTIC (3-methyl-
(triazen-1-yl)imidazole-4-carboxamide), which is an
alkylating agent [35]. It is also a radiosensitizer, and is
therefore a key component of chemo-radiation therapy for
glioblastomas [36]. The microdialysis catheters were
inserted after tumour resection, within 5 mm of the
resection cavity. Temozolomide was determined in blood
plasma and brain ECF from seven patients using liquid
chromatography–tandem mass spectrometry (LC–MS/MS)
[34]. The recovery of the drug by microdialysis was mea-
sured in vitro, and patients’ results were adjusted accord-
ingly. Retrodialysis recovery determination in vivo for
catheter calibration was unfeasible because temozolomide
was only available in a non-sterile oral formulation.
Pharmacokinetic parameters for temozolomide in
plasma and brain ECF were determined using non-com-
partmental pharmacokinetic methods [34]. As a measure of
brain penetration, the mean brain-to-plasma AUC ratio was
0.178 (range 0.019–0.332). This is similar to the ratio of
temozolomide in CSF to plasma reported by Osterman
et al. [37], which was 0.2. The time of maximum con-
centration (Tmax) in the brain ranged from 1.2 to 3.4 h
(average 2.0 h), compared with between 0.5 and 4.0 h
(average 1.8 h) in the blood. The concentration of drug in
brain ECF generally rose more slowly and stayed elevated
for longer compared to the drug in plasma (elimination
half-life in plasma was 2.1 h average, while the elimination
half-life in brain ECF was 2.9 h average).
The authors discuss the importance of their Tmax mea-
surements in the context of the drug being used as a radi-
osensitizer before administration of radiation therapy [34].
It is typically given 1 h before radiotherapy, because pre-
vious results showed that the drug peaked in plasma 1 h
after an oral dose. The authors suggest that this may be
suboptimal because the Tmax in brain is 2 h after oral dose.
As it happens, the average Tmax for plasma in their study is
close to 2 h also (1.8 h). Findings from microdialysis may
thus be useful for optimising the efficacy of therapies and
designing better protocols.
This study also confirms a prediction made by Zhou
et al. [38] that the brain-to-plasma AUC ratio would be 0.2
in humans. This prediction was made using microdialysis
to measure the pharmacokinetics of temozolomide in rat
brain, and subsequent scaling up to predict drug concen-
trations in human brain.
As discussed in the last section, one of the issues asso-
ciated with cerebral microdialysis studies on both severely
head injured patients and cerebral tumour patients is that
there may be BBB impairment in the region of the catheter,
leading to increased permeability. This may be useful in
getting sufficient concentration of drug into the brain, but
could also be damaging if the dose is too high. The extent
of BBB impairment can be measured using dynamic con-
trast-enhanced magnetic resonance imaging (DCE-MRI)
[39]. This procedure, which is used for the radiographic
assessment of brain tumours, involves taking an MRI scan
after intravenous administration of a gadolinium based
contrast agent, e.g. gadopentetic acid (Magnevist) and
gadobutrol (Gadovist). The contrast agent is confined to the
intravascular space until it passes through a region of BBB
breakdown where it can permeate into the extravascular
space. These regions then show up in the MRI scan as
contrast-enhanced compared to normal regions of the brain.
Blakeley et al. [40] used microdialysis to study the
pharmacokinetics of the chemotherapy drug methotrexate
in four patients following tumour resection. The authors
also used DCE-MRI, in conjunction with computerized
tomography (CT) scanning, to report the integrity of the
BBB at the exact position of the catheter tip. The micro-
dialysis probe has a gold tip and is visible in the CT scan.
Pharmacokinetic analysis showed that the extent of pene-
tration of drug into the brain after infusion depended on the
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integrity of the BBB in the region of the catheter. If the CT
and MRI scans showed that the catheter tip was in a region
of BBB disruption, a higher concentration of drug was
found: the AUC ratio of brain-to-plasma was 0.281 and
0.305 in these two patients. When the catheter was placed
in a contrast non-enhancing region of the tumour, where
there was minimal disruption of the BBB, the AUC ratio of
brain-to-plasma was much lower, 0.032 and 0.094 for two
patients. Another finding was that the rate of decline in
brain ECF drug concentration was similar to the rate of
decline in plasma drug concentration for the damaged
BBB, but elimination from the brain was considerably
slower when the BBB was intact (Fig. 5). The authors
suggest that there is free exchange of unbound drug mol-
ecules between blood and brain ECF in regions where the
BBB is disrupted.
Researchers know what concentration of chemotherapy
drug is required to kill tumour cells from in vitro work. The
average concentration of methotrexate required for 50 %
cell kill against various glioma cell lines after 72 h of
incubation was reported to be 2.4 lM [41]. Even in the
contrast non-enhancing (intact BBB) regions of the tumour,
much higher peak concentrations of methotrexate were
found. Also, in both sets of patients, the time that brain
ECF methotrexate concentration exceeded 2 lM ranged
from 20 to 26 h. Thus, the minimum requirement of
achieving a potentially cytotoxic concentration within the
tumour was attained with methotrexate at the dose used.
This small study was thus highly informative, and the
authors suggested that phase II trials of chemotherapy
drugs should only be carried out if it has first been dem-
onstrated in early clinical studies like this one that thera-
peutic concentrations in tumour are achievable. Otherwise,
without such information, phase II trials may waste valu-
able resources and patients who could be enrolled into
other studies.
Out of the ten patients that were initially recruited for
this study, six failed to complete. A high failure-to-com-
plete rate is often one of the pitfalls of small studies like
this one. The causes for failure in this study included two
patients that were found to have the wrong grade of tumour
and two patients that did not receive the drug as specified in
the study design. Technical malfunctions accounted for
another two failures: a microdialysis catheter membrane
ruptured in one case and in another there was a faulty
connection between syringe pump and tubing.
Neuroprotective agents
Microdialysis has been used to study the effects of poten-
tially neuroprotective drugs on neurochemical analytes in
patients suffering from TBI.
Cyclosporin A (CsA) is a cyclic peptide (1,203 Da) that
is used widely as an immunosuppressant in organ trans-
plantation. It is also being developed as a neuroprotective
agent for use in the early phase after TBI because of its
ability to preserve mitochondrial activity by inhibiting the
opening of the mitochondrial permeability transition pore
[42]. Mazzeo et al. [43] used microdialysis to assess the
effect of CsA on brain energy metabolism and brain hae-
modynamics in a randomized, double blind, placebo-
controlled study on 50 patients with severe head injury. In
addition to monitoring neurochemistry and brain hemody-
namics, a second paper reports the clinical safety and tol-
erability results for the given dose [44]. Also, incidences of
adverse events in the first week and overall neurological
outcome at 3 and 6 months were reported.
The main finding in the microdialysis study by Mazzeo
et al. [43] was that the concentration of glucose in brain
ECF was significantly higher in the CsA treated patients
than in the patients that received a placebo. This elevation
Fig. 5 Pharmacokinetics of methotrexate, from a study by Blakeley
et al. [40]. ‘‘Time courses of the MTX concentration in plasma (white
circle) and brain ECF (white diamonds). The plasma profiles are
similar in each of the four patients, with peak drug levels ranging
from 1,321 to 1,407-lM at the end of the 4-h i.v. infusion of MTX
12 g/m2. Time courses of MTX in ECF are dependent upon whether
the probe of the microdialysis catheter was placed in contrast
enhancing (patients a and b) or non-enhancing (patients c and d)
regions of the tumor.’’ Reproduced with kind permission from
Springer Science?Business Media: Journal of Neuro-oncology,
Effect of blood–brain barrier permeability in recurrent high grade
gliomas on the intratumoral pharmacokinetics of methotrexate: a
microdialysis study, vol. 91, 2012, pp. 51–58. Blakeley JO, Olson J,
Grossman SA, He X, Weingart J, Supko JG, Fig. 2
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of glucose lasted for at least 2 days after the 24 h infusion
of CsA was complete. Both pyruvate and lactate were also
higher in the CsA patients. The CsA infusion raised brain
extracellular glucose up into the normal range for the entire
period of study [45], whereas the brain glucose in patients
given placebo was below the normal range for most of this
period. This apparent normalisation of brain glucose
appeared independent of plasma glucose, so was attributed
to a cerebral mechanism. The significantly higher micro-
dialysate lactate in the CsA patients compared to those
given placebo appeared to refute the original hypothesis
that CsA would improve mitochondrial function. Lactate is
a product of glycolysis and its increase is indicative of
mitochondrial dysfunction or (if relevant) lack of oxygen.
However, lactate is also a fuel for neurons, so lactate
increase per se is not necessarily deleterious, especially as
microdialysate pyruvate concentration also increased,
suggesting some preservation of mitochondrial function, in
the CsA group compared with placebo. An important
indicator is the microdialysate lactate/pyruvate (L/P) ratio,
which was similar in both CsA and placebo groups during
the 24 h of infusion, while at 3 and 4 days post-infusion the
L/P ratio was significantly lower in the CsA group, sug-
gesting an improvement in energy metabolism.
The mean peak concentration of CsA in CSF was
2.08 ng/ml during the 24-h infusion of the drug [43]. CsA
concentrations detected in microdialysates ranged from
zero to 0.61 ng/ml, without adjustment for relative recov-
ery (G.M. Brophy—personal communication). Both the
CSF and microdialysis data suggested very limited brain
uptake, in view of the much higher mean steady-state
concentration of CsA in whole blood, which was 545 ng/
ml during the infusion. However, the in vitro recovery of
CsA using the microdialysis catheters is also very low. Due
to its lipophilic nature, CsA binds non-specifically to glass
and plastic (PVC) surfaces [46], and probably to the
microdialysis membrane. So, although the administration
of CsA causes a significant change in brain chemistry, the
concentration of drug in the brain ECF required to achieve
the effect is still not known.
In the second paper looking at the safety and tolerability
of CsA, Mazzeo et al. [44] assess the effect of CsA on renal
function, hepatic function, blood cell parameters, occur-
rence of adverse events and neurological outcome at 3 and
6 months. They found no difference in neurological out-
come between the CsA patients and the placebo patients,
suggesting that the elevated glucose concentrations in the
brain had no effect on outcome.
In contrast, a study by Hatton et al. [47] showed a dose-
related improvement in favourable outcome when patients
were given CsA within 8 h of injury. These authors suggest
that TBI may temporarily alter the BBB permeability and
there may be a window of dosing opportunity when CsA
can penetrate the BBB. The authors speculate that if the
CsA is administered within 8 h, the drug can find its way
into the brain where it can have its neuroprotective effects.
Sullivan et al. [48] suggest the reason why Mazzeo’s study
[44] failed to show an outcome was that CsA was admin-
istered after the 8-h window. Of course, the only way to
prove this would be to accurately determine the concen-
tration of CsA in brain ECF.
Anticonvulsant drugs
One of the challenges in treating epilepsy is that up to 30 % of
patients continue to have seizures even when they are
receiving anti-epileptic drug treatments, i.e. refractory epi-
lepsy. The causes are not known, but inadequate drug con-
centration in crucial brain areas is a possible contributing
factor. One reason for this may be over-expression of efflux
transporters in patients with epilepsy in response to adminis-
tration of antiepileptic drugs, as was found for phenytoin [49].
An anticonvulsant drug of interest is vigabatrin
(gamma-vinyl-gamma-aminobutyric acid), an inhibitor of
GABA-transaminase (GABA-T), an enzyme responsible
for degrading GABA. Vigabatrin is thus regarded as neu-
roprotective, and has been studied by cerebral microdi-
alysis in TBI patients (0.5 g every 12 h, enterally) with
multimodality monitoring and a preliminary report pub-
lished [50]. Vigabatrin is a small water-soluble molecule
(129 Da) and, as expected, is efficiently recovered by
microdialysis (in vitro recovery 100 %, R.J. Shannon
unpublished observation). Microdialysis results from three
patients are illustrated in Fig. 6, showing that vigabatrin
levels rose in brain microdialysates, followed by modest
increases in GABA [50]. Vigabatrin and GABA levels
increased more in abnormal brain (patient C, Fig. 6d) than
in sites further from lesions (patients W and R, Fig. 6b, c),
and were higher after multiple vigabatrin doses than after
one dose. Highest vigabatrin and GABA levels were 75 and
4 lM respectively. Vigabatrin did not overtly affect
intracranial pressure and other pressure parameters, or
microdialysate lactate, pyruvate and L/P ratio in this pre-
liminary evaluation [50]. This study has demonstrated
(albeit in a small number of patients) the principle that
multimodality monitoring, including cerebral microdialy-
sis, is feasible for studying surrogate end-points following
administration of a putative neuroprotective drug.
Challenges and solutions
Limitation of patient numbers
Human cerebral microdialysis is an invasive technique,
which limits its applicability because the catheter must be
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surgically implanted into the brain. Examples of eligible
patients are those requiring surgery for brain tumour
resection or requiring treatment for TBI in NCCUs. There
are a very limited number of these patients available to
study, so only small observational studies or limited clin-
ical trials are feasible.
Variability of microdialysis results
The patients recruited into cerebral microdialysis studies
usually have traumatic or non-traumatic brain injuries or
tumours. Results obtained from a study on such patients
might not necessarily extrapolate to the kind of patient
most likely to benefit from the drug being studied. Also, as
illustrated in this review, there can be significant variation
in the brain permeability of a drug between patients in the
study. This is because brain injuries or tumour growth can
cause BBB disruption, which can be slight or severe,
localised or general. The position of the microdialysis
catheter with respect to brain injury or tumour is therefore
an additional variable in these studies.
Microdialysis recovery of drug from the brain ECF
There are several reasons why a drug may be poorly
recovered from brain ECF by microdialysis. Lipophilic
molecules have been shown to bind non-specifically to
various parts of the microdialysis catheter (e.g. membrane
and/or tubing) [51]. Researchers have included additives in
the microdialysis perfusion fluid, including albumin [52]
and b-cyclodextrin [53], in attempts to improve the
recovery of lipophilic molecules.
Non-recovery of a drug from the brain ECF may be
simply because it is not there. Unless the drug is small and
lipophilic, it can only enter the brain if it is a substrate for a
BBB transporter or if the BBB is disrupted [5]. Even if a
drug does enter the brain, it may be efficiently exported
back across the BBB by efflux transporters, e.g. P-gp and/
or MRPs. This is the brain’s self-defence mechanism that
has presumably evolved naturally as a protection against
harmful substances, and which often works against the
development of new neuroactive drugs. Another reason for
a drug not being detected in the brain ECF is that it may be
Fig. 6 Levels of vigabatrin (VGB) and GABA in TBI patients versus
time, adapted from Carpenter et al. [50]. VGB was administered
enterally (0.5 g twice daily). a Concentrations (mean ± SD) of VGB
(lmol/L) in blood plasma for the first half-day following the first
VGB dose, for five patients. b Concentrations of VGB (lmol/L)
(indicated by black diamonds) and GABA (lmol/L) (grey triangles)
versus time in brain microdialysates from patient W (male, 17 years,
admission GCS 3). Day 0 is the day of injury. Microdialysis started on
day 3 post-injury, and VGB treatment commenced on day 4 (18:00).
Data are for the first 1.5 days of VGB administration. The times of
VGB doses are indicated by grey squares. c Concentrations of VGB
(lmol/L) and GABA (lmol/L) in brain microdialysates from patient
R (male, 33 years, admission GCS 14) versus time, for the first
2.5 days of VBG administration. Microdialysis commenced on day 1
post-injury, and VGB treatment commenced on day 6 (23:05).
Symbols are as in panel (b). d Concentrations of VGB (lmol/L) and
GABA (lmol/L) versus time in brain microdialysates from patient C
(male, 66 years, admission GCS 7) for the first 8.5 days of VGB
administration. Symbols are as in panel (b). Microdialysis com-
menced on day 2 post-injury, and VGB treatment commenced on day
3 (22:00). There was a gap of 36 h between the sixth and seventh
doses
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rapidly taken up by cells, or become bound to extracellular
matrix, or be extensively metabolised by cells.
In vivo recovery experiments
Several techniques exist for calculating relative recovery
in vivo. One of these is the extrapolation-to-zero-flow
technique [29] [2]. This involves varying the flow rate
through the microdialysis catheter. As the flow rate falls,
recovery will rise as the microdialysate has more time to
equilibrate with the ECF. The logarithm of the concentra-
tion of the substance of interest (y-axis) is plotted against
flow rate (x-axis) and a line fitted to the data points.
Extrapolating this fitted line to zero flow (i.e. determining
the intercept on the y-axis) gives the ‘‘true’’ ECF concen-
tration of the substance, and enables calculation of relative
recovery at each of the flow rates previously employed.
This technique has the disadvantages that it is time-con-
suming and relies on the concentration of the substance of
interest remaining constant in the ECF while the flow rate
variations are being carried out. Such constancy cannot be
assumed in a complex biological environment, and so a
reference catheter is employed at a constant flow rate in
nearby tissue to detect fluctuations and enable the con-
centrations to be corrected for the test catheter, a procedure
that in turn relies on certain assumptions. The extrapola-
tion-to-zero flow method is not practicable in pharmaco-
kinetic studies.
Another in vivo recovery determination method is ret-
rodialysis-by-drug, as used by Dahyot-Fizelier et al. [18] in
their meropenem study (see above). This involves perfus-
ing the microdialysis catheter with a known concentration
(Cin) of drug until the emerging concentration (Cout) of
drug in the microdialysate is steady. Relative recovery is
calculated from the concentration difference expressed as a
percentage, i.e. relative recovery = 100 9 (Cin - Cout)/Cin.
Retrodialysis by calibrator, i.e. a substance chosen as being
closely related to the drug, is another variant of the method
[54]. Retrodialysis-by-drug is widely used in pharmacoki-
netic studies, but it is unsuitable for determining relative
recoveries of endogenous molecules.
A further in vivo recovery determination method is the
no-net-flux method [2, 55]. The concentration of the sub-
stance of interest, e.g. drug, is varied in the perfusate. If the
concentration of drug in the perfusate (Cin) is greater than
in the surrounding ECF then the substance will diffuse out
of the perfusate into the ECF, so the emerging concentra-
tion of drug in the microdialysate (Cout) is lower than Cin.
Conversely, if the ECF concentration of the drug is higher
in the ECF than in the perfusate, then the drug will diffuse
out of the ECF into the perfusate, so the emerging micro-
dialysate Cout will be higher than Cin. A plot of the
difference between Cin and Cout (Cdiff, y-axis) versus
Cin (x-axis) is then constructed, and a line is fitted. The
concentration at which Cdiff is zero (i.e. where the line
crosses the x-axis) is the ‘‘true’’ concentration of the sub-
stance in the ECF. While this method is often regarded as
the ‘‘gold standard’’ and is suitable for both endogenous
and exogenous substances, it has the disadvantage that it
needs to be done at a steady state and is not suitable under
transient conditions.
In vivo recovery experiments such as retrodialysis are
not always feasible. For example, when the drug is not
available in a formulation suitable for retrodialysis or when
direct perfusion of drug into the brain may cause adverse
events such as seizures. In these cases, the recovery rates
can only be estimated e.g. from in vitro bench tests. Even
so, useful information can still be obtained from patients by
comparing changes in concentrations over time, e.g. before
and after dose, and accompanying changes in any other
relevant analytes (e.g. glucose, lactate, pyruvate etc.) and/
or downstream target molecules of the drug.
Regular and continuous sampling
One of the advantages of microdialysis is that it is a con-
tinuous-flow technique. In the NCCU, microdialysis col-
lection vials are routinely changed every hour, enabling
detailed time-course measurement of drug concentration.
However, because the care of the patient is the primary
concern, microdialysis sampling may not always be opti-
mal for the purposes of drug pharmacokinetic studies. For
example, the patient may be moved for a scan or operation
and the microdialysis pump temporarily disconnected for
the duration. Other essential procedures on the ward may
mean that vial change times are disrupted. Also, occa-
sionally there can be malfunctions in microdialysis pumps
and/or catheters. Such irregularities can pose problems for
pharmacokinetic studies.
Regional distribution in brain
A drug may produce its therapeutic effect in one region of
the brain, but actually accumulate in a different region of
the brain. Kornhuber et al. [56] have reported region-spe-
cific distribution of the neuroleptic drug levomepromazine
in post-mortem brain tissue. The authors looked at brain
tissue samples from 15 subjects who had been treated
orally with either levomepromazine or haloperidol, both
neuroleptic drugs. They found that levomepromazine dis-
tributed unevenly, with a significant difference between the
cortex and the basal ganglia regions. The analysis of brain
tissue does not distinguish between unbound drug and cell-
associated drug. However, this study does illustrate that a
drug may accumulate in one region in preference to
another, which is important to bear in mind in
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microdialysis studies of patients. Microdialysis is a very
focal technique, so the microdialysis catheter needs to be
placed in a relevant, clinically valid site. Although in some
patients it is possible to insert two microdialysis catheters,
to compare different sites, microdialysis cannot provide
broad regional or global information. Combined microdi-
alysis and scanning studies may be more relevant in this
context.
Genetic polymorphism and BBB transporters
in patients
A considerable amount is known about BBB transporters
and their substrates (for example, see Taylor et al. [57]). Of
these, the best characterised is P-gp, also termed multidrug
resistance protein or MDR-1, which is a member of the
ATP-binding superfamily [59, 60]. P-gp is ubiquitous at
many endo- and epithelial barriers, not least the BBB, and
may act as an efflux transporter for up to 50 % of clini-
cally important drug compounds. Correspondingly, P-gp
knockout animals can show 10- to 100-fold increases in
brain concentrations of drugs that are substrates for this
transporter [58].
Certain genetic polymorphisms in P-gp have emerged as
potentially important in determining the efficacy and
incidence of adverse effects of specific neuroactive drugs.
For example, two single nucleotide polymorphisms in P-gp
have been associated with clinically significant increase in
side effects of the dopamine agonist cabergoline [59]. In
contrast, Brunner et al. [60] carried out a PET study to find
out if patients with P-gp variants had altered penetration of
the labelled molecule 11C-verapamil and found no differ-
ence between the two groups above inter-individual vari-
ability, concluding that genetic variants of P-gp had no
significant effect on BBB penetration of this specific drug.
Overall, it is still largely unclear how to predict the mag-
nitude of effect that common P-gp polymorphisms will
have on CNS bioavailability for any individual drug [12].
Consequently, careful consideration should be given to
genetic profiling of patients in microdialysis pharmacoki-
netic studies as polymorphisms in efflux transporters may
be an important source of observed variability in CNS drug
concentrations.
Measuring the integrity of the blood brain barrier
Transport of drugs across the BBB can be passive or active.
Passive transport increases if the integrity of BBB is
compromised. The BBB is dynamically controlled by
components in the blood and in brain ECF. For instance,
inflammatory mediators released from astrocytes may
affect transport across the BBB. Dynamic regulation of the
BBB means that its behaviour may vary in different
situations.
Beyond assessing the penetration of individual drugs
into the CNS, microdialysis could be employed to measure
the general integrity of the BBB. In diverse pathological
conditions the apical tight junctions between endothelial
cells that inhibit passive diffusion are disrupted through
proteolysis and down-regulation of their component pro-
teins. Key mediators commonly implicated in this process
are vascular endothelial growth factor (VEGF), matrix
metalloproteinases (MMPs, particularly -2 and -9), and
nitric oxide [61–63]. Where the BBB is no longer effective
there is potential to develop vasogenic oedema and swell-
ing with resulting brain shift and raised intracranial pres-
sure, both of which have adverse implications on patient
outcomes.
The degree of BBB impairment is usually quantified by
measuring interstitial brain concentrations of a tracer
compound to which the BBB is normally impermeable
following bolus intravascular injection. Tracers with a
range of molecular weights can be employed to gauge the
severity of BBB disruption. Common low molecular
weight tracers include radiolabelled sucrose or fluoro-
phores such as fluorescein; larger molecular weight tracers
include fluorescent or radiolabelled albumin and dextrans
[64, 65]. In animal studies the extent of extravasation is
typically assessed by autoradiography or microscopy of
brain slices, or assayed directly in tissue homogenate. In
humans, non-invasive radiological techniques to measure
BBB permeability utilise dynamic computed tomography
or magnetic resonance imaging (MRI) following intrave-
nous injection of iodinated or paramagnetic contrast agents,
respectively [66, 67]. In the microdialysis study described
in section entitled ‘‘Drugs for tumour therapy’’, Blakeley
et al. [40] used dynamic contrast enhanced MRI to measure
BBB permeability. Alternatively, there are also SPECT and
PET tracers, usually radiolabelled EDTA or DTPA, which
have been synthesised for measuring BBB permeability
in vivo [70, 71].
Microdialysis has the potential to be used for in vivo
monitoring of BBB permeability using a similar paradigm,
with several potential advantages. The ideal tracers would
be endogenous plasma molecules that do not normally
cross the BBB (e.g. albumin) [68], although serial injection
of exogenous tracer would also be feasible [69]. The
principal benefits of a microdialysis approach to measuring
BBB integrity would be continuous, potentially on-line,
in vivo assay of multiple tracers of differing molecular
weights, as opposed to one-time ‘snapshots’ of perme-
ability to a single contrast agent provided by CT or MRI.
Nonetheless, microdialysis cannot provide the spatial
coverage of CT or MRI and these techniques should be
viewed as complementary.
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This application of microdialysis would be particularly
useful for determining the efficacy of therapeutic strategies
targeted at reducing BBB permeability and brain oedema in
conditions such as TBI.
Dynamic contrast-enhanced MRI has been used to
detect subtle changes in the BBB [70], and while other
researchers have highlighted the need for further technical
development [71], the technique has potential for studying
TBI patients. Other BBB measurement methods exist, such
as perfusion CT with iodinated contrast agents [66] (see
above). However it should be borne in mind that BBB
permeability is not a simple phenomenon and will vary
depending on the molecular species in question.
Comparing extracellular and intracellular
concentrations
Microdialysis measures extracellular concentrations, and
cannot measure intracellular concentrations of molecules.
However, microdialysis can be usefully employed to
complement scanning techniques that measure total tissue
concentrations. For example, Langer et al. [72] studied the
intracellular drug pharmacokinetics of 18F-ciprofloxacin
using a combined microdialysis and PET study. Although
this study was in human muscle, it illustrates a principle
that could potentially be applied in human brain, and such
studies have been carried out in animals [73]. PET mea-
sures total radiolabelled drug concentration (extracellular,
intracellular and intravascular), and microdialysis measures
extracellular concentration. Therefore the difference gives
a method to measure the pharmacokinetics of the drug
intracellular concentration.
Conclusions and future prospects
Cerebral microdialysis is proving its worth as a clinical
monitoring technique for severe brain injury, in which
fundamental molecules, such as glucose, lactate and
pyruvate, are measured at the bedside [74, 75], and is
increasing its applicability to the study of drugs in the
human brain as exemplified in the present review. As well
as microdialysis providing drug concentration data in the
brain ECF, the ability to simultaneously measure other
biomarkers within the microdialysate may provide a
method for assessing the downstream effects of pharma-
cological agents. For example, microdialysis can reveal
valuable information on whether putative neuroprotective
agents can improve brain chemistry in terms of L/P ratio,
glucose etc.
Microdialysis is the only existing technique for sam-
pling molecules from the brain ECF. As an invasive
technology, it is limited to certain categories of patient—
those requiring neurocritical care and/or neurosurgery—but
this is not necessarily such a drawback in itself as such
patients are likely to benefit from development of CNS
drug therapies, and extrapolation to related patient groups
seems possible, such as certain forms of epilepsy. How-
ever, there is a much larger and well-recognised need for
better CNS drugs to treat chronic neuro-pathologies that
appear more widespread in the general population, such as
multiple sclerosis and Alzheimer’s disease. Such patients
are currently inappropriate for the degree of invasiveness
inherent in cerebral microdialysis. For the present, cerebral
microdialysis in neurocritical care and/or neurosurgery
patients can provide surrogate information that may be
relevant in general terms of neuroprotection strategies.
Small phase II clinical trials utilising cerebral microdialysis
would seem crucial precursors to deciding on which drugs
are promising enough to progress to larger, more costly
trials. Cerebral microdialysis may also pave the way for
future technology development. In the longer term, sensor
devices that are smaller and less invasive than the existing
microdialysis catheters may be developed for implantation
into brain, and open up new prospects for CNS drug
development.
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